PhySH "Physician Scientist Hour"
INDE 217 : Physician Scientist Hour (PhySH)
Mondays at 12:15pm - 1:15pm
Please register for PhySH - INDE 217
(You are not required to register to attend.)
You might also be interested in the TRAM lecture series, which hosts speakers who are recognized leaders in translational research and applied medicine. Please see the Translational Research and Applied Medicine website for more information.
Spring 2022 PhySH Schedule
We will provide updates as information becomes available.
March 28, 2022
The future of healthcare: You
Dr. Freda Lewis-Hall is widely regarded for expanding outreach to patients, reshaping the focus on patient engagement and inclusion, improving health information and education, and amplifying the voice of the patient within company culture and decision-making. She served in various leadership roles at a number of pharmaceutical companies, most recently as Chief Medical Officer and Executive Vice President, and later Chief Patient Officer, at Pfizer.
April 4, 2022
How to give a talk
Dr. Matt Porteus is an Associate Director of the Stanford MSTP. The Porteus lab focuses on developing genome editing by homologous recombination as curative therapy for children with genetic diseases but also has interests in the clonal dynamics of heterogeneous populations and the use of genome editing to better understand diseases that affect children including infant leukemias and genetic diseases that affect the muscle.
April 11, 2022
April 18, 2022
April 25, 2022
May 2, 2022
May 16, 2022
Student Fellowship/F30 Session: MSTP student panel
June 23, 2022
Winter 2022 PhySH Schedule
January 10, 2022
Chromatin-mediated gene control: Single-cell and high-throughput measurements
The Bintu lab performs single-cell and high-throughput measurements of chromatin and gene regulation dynamics, and uses these data to develop predictive models and improve mammalian cell engineering.
Katherine J. Wu
January 24, 2022
A Q&A session
Dr. Katherine J. Wu is a staff writer for The Atlantic, where she covers science. She is also a Story Collider senior producer and a senior editor at The Open Notebook. She previously served as a science reporter for The New York Times, where she reported on the COVID-19 pandemic. She’s also been a staff writer for NOVA Next, an early career fellow at the Open Notebook, and a AAAS Mass Media Fellow at Smithsonian magazine.
January 31, 2022
Grant writing: F30
The Blish Lab strives to develop new methods to prevent and control infectious diseases through better understanding of human immunology. The lab has several major areas of ongoing investigation: understanding the diversity and biology of human natural killer (NK) cells; defining the role of NK cells in viral immunity; and immune signatures of human pregnancy.
Ronald D. Vale
February 7, 2022
The serendipity of a scientific career
Vale’s research has focused on how cargoes are transported within cells using molecular motor proteins. Vale discovered the motor protein “kinesin,” and his laboratory was involved in elucidated its mechanism of movement using structural and single-molecule approaches. For the past fifteen years, Vale has investigated the mechanism of dynein, a much larger and more complex molecular motor. His lab also discovered and studied proteins that sever, nucleate, and cap microtubules. Currently, his laboratories studies T cell and macrophage signaling, RNA biology and phase separation, the role of the cytoskeleton in tissue organization, and the regulation of ciliary motility.
MSTP Diversity Working Group (DWG)
February 14, 2022
Panel discussion with the Stanford Medicine Alliance for Disability Inclusion and Equity (ADIE)
The DWG comprises of MSTP students from diverse backgrounds who meet regularly to discuss strategies to evaluate and improve diversity, equity, and inclusion within the MSTP and throughout Stanford. The DWG focuses on strategies for supporting current students, as well as Outreach/Recruitment and Admissions.
Stanford Medicine Alliance for Disability Inclusion and Equity (ADIE)
February 28, 2022
Peer review (RCR)
The Felsher’s lab investigates how oncogenes initiate and sustain tumorigenesis. They developed model systems whereby they can conditionally activate oncogenes in normal human and mouse cells in tissue culture or in specific tissues of transgenic mice. In particular using the tetracycline regulatory system, they generated a conditional model system for MYC-induced tumors. They showed that cancers caused by the conditional over-expression of the MYC proto-oncogene regress with its inactivation. Thus, even though cancer is a multi-step process, the inactivation of one oncogene can be sufficient to induce tumor regression. They are now using these model systems to address how oncogenes initiate tumorigenesis, how oncogene inactivation cause tumor regression, and how tumors escape dependence on oncogenes.
Autumn 2021 PhySH Schedule
September 20, 2021
Managing up, down and across: How to have productive, stress-free relationships at work (RCR)
Dr. Boothroyd’s research interests have spanned from viruses such as bacteriophage T7 and Foot and Mouth Disease Virus through to protozoan parasites such as Trypanosoma brucei, the cause of African sleeping sickness, and Toxoplasma gondii, a serious pathogen in newborns and individuals who are immunocompromised. Currently, his lab is focused on the interaction between the animal host and Toxoplasma. Together with their collaborators, the lab asks: (1) how does Toxoplasma invade and co-opt almost any cell type from almost any animal; (2) once in, how does it persist in its hosts for their entire lifetime; and 3) how do the polymorphic “effectors” that Toxoplasma injects into a host cell produce different disease outcomes.
Allison Rustagi (UCSF)
October 4, 2021
Parenting as a physician-scientist: Research, personal stories, and opportunities for change
Dr. Rustagi obtained a bachelor’s in Human Biology from Stanford University, an M.D. from UCSF and a Ph.D. in Epidemiology from the University of Washington, in which she found cervical cancer screening reduces mortality among women even up to age 79. During her post-doctoral Fellowship in Global Health at the University of Washington, she conducted a cluster randomized trial of quality improvement interventions in sub-Saharan Africa, which increased uptake of interventions that reduce mother-to-child HIV transmission. Her current research focuses on implementation of lung cancer screening in the VA; she also has an interest in gender discrimination in medicine.
October 11, 2021
Understanding and modeling aging
Dr. Brunet’s lab is interested in the molecular mechanisms of aging and longevity, with a particular emphasis on the nervous system. Her lab is interested in identifying pathways involved in delaying aging in response to external stimuli such as availability of nutrients and mates. She also seeks to understand the mechanisms that influence the rejuvenation of old stem cells. Finally, her lab has pioneered the naturally short-lived African killifish as a new model to explore the regulation of aging and age-related diseases.
October 18, 2021
From parasites to plankton: The opportunities and challenges of switching fields
Dr. Yeh’s research focuses on the apicoplast, a prokaryotically-derived plastid organelle unique to Plasmodium (and other pathogenic Apicomplexa parasites) and a key anti-malarial drug target. Her laboratory's goal is to elucidate apicoplast biology, function, and role in pathogenesis with the ultimate goal of realizing the potential of the apicoplast as a therapeutic target.
October 25, 2021
Dr. Abu-Remaileh’s lab is interested in identifying novel pathways that enable cellular and organismal adaptation to metabolic stress and changes in environmental conditions. It also study how these pathways go awry in human diseases such as cancer, neurodegeneration and metabolic syndrome, in order to engineer new therapeutic modalities. By examining 1) how the lysosome communicates with other cellular compartments to fulfill the metabolic demands of the cell under various metabolic states, 2) and how its dysfunction leads to rare and common human diseases, his lab hopes to engineer novel therapies to modulate the pathways that govern human disease..
November 1, 2021
High-throughput genomics in cancer immunotherapy
Dr. Satpathy’s lab works at the interface of immunology, cancer biology, and genomics to study cellular and molecular mechanisms of the immune response to cancer. In particular, it is leveraging high-throughput genomic technologies to understand the dynamics of the tumor-specific T cell response to cancer antigens and immunotherapies (checkpoint blockade, CAR-T cells, and others). The lab is also interested in understanding the impact of immuno-editing on the heterogeneity and clonal evolution of cancer.
November 8, 2021
Dr. Idoyaga’s lab is focused on the function and biology of dendritic cells, which are specialized antigen-presenting cells that initiate and modulate our body’s immune responses. Considering their importance in orchestrating the quality and quantity of immune responses, dendritic cells are an indisputable target for vaccines and therapies.
MSTP Town Hall
November 15, 2021